116 related articles for article (PubMed ID: 10718121)
1. Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem.
Trieu L; Murray M
Xenobiotica; 2000 Feb; 30(2):131-40. PubMed ID: 10718121
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites.
McNeil CM; Murray M
Biochem Pharmacol; 1996 Jan; 51(1):15-20. PubMed ID: 8534263
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines.
Murray M; Murray K
Xenobiotica; 2003 Oct; 33(10):973-87. PubMed ID: 14555335
[TBL] [Abstract][Full Text] [Related]
4. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
5. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants.
Murray M; Field SL
Biochem Pharmacol; 1992 May; 43(10):2065-71. PubMed ID: 1599495
[TBL] [Abstract][Full Text] [Related]
6. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline.
Murray M
Mol Pharmacol; 1992 Nov; 42(5):931-8. PubMed ID: 1435757
[TBL] [Abstract][Full Text] [Related]
7. In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats.
Levine M; Law EY; Bandiera SM; Chang TK; Bellward GD
J Pharmacol Exp Ther; 1998 Feb; 284(2):493-9. PubMed ID: 9454789
[TBL] [Abstract][Full Text] [Related]
8. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
9. Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes.
Yamazaki H; Shimada T
Xenobiotica; 1998 Oct; 28(10):995-1004. PubMed ID: 9849646
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
Grubb MF; Diamond S; Christ DD
Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
[TBL] [Abstract][Full Text] [Related]
11. Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes.
Amacher DE; Schomaker SJ
Toxicol Lett; 1998 Jan; 94(2):115-25. PubMed ID: 9574808
[TBL] [Abstract][Full Text] [Related]
12. Comparative inhibition of inducible and constitutive CYPs in rat hepatic microsomes by parathion.
Murray M; Butler AM
Xenobiotica; 2004 Aug; 34(8):723-39. PubMed ID: 15690761
[TBL] [Abstract][Full Text] [Related]
13. Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation.
Murray M; Butler AM
J Pharmacol Exp Ther; 1996 Dec; 279(3):1447-52. PubMed ID: 8968370
[TBL] [Abstract][Full Text] [Related]
14. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.
Hanson KL; VandenBrink BM; Babu KN; Allen KE; Nelson WL; Kunze KL
Drug Metab Dispos; 2010 Jun; 38(6):963-72. PubMed ID: 20200233
[TBL] [Abstract][Full Text] [Related]
15. Comparative induction of CYP3A and CYP2B in rat liver by 3-benzoylpyridine and metyrapone.
Murray M; Sefton RM; Martini R; Butler AM
Chem Biol Interact; 1998 Jun; 113(3):161-73. PubMed ID: 9717516
[TBL] [Abstract][Full Text] [Related]
16. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats.
Ohnishi N; Kusuhara M; Yoshioka M; Kuroda K; Soga A; Nishikawa F; Koishi T; Nakagawa M; Hori S; Matsumoto T; Yamashita M; Ohta S; Takara K; Yokoyama T
Biol Pharm Bull; 2003 Sep; 26(9):1315-20. PubMed ID: 12951478
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
18. The xenobiotic inhibitor profile of cytochrome P4502C8.
Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of n-hexane by rat liver and extrahepatic tissues and the effect of cytochrome P-450 inducers.
Crosbie SJ; Blain PG; Williams FM
Hum Exp Toxicol; 1997 Mar; 16(3):131-7. PubMed ID: 9088965
[TBL] [Abstract][Full Text] [Related]
20. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
